{"meta":{"id":"https:\/\/api.iclient.ifeng.com\/ipadtestdoc?aid=ucms_7zPZpbCnDLh","type":"doc","o":"1","documentId":"ucms_7zPZpbCnDLh"},"body":{"newStatus":"1","documentId":"ucms_7zPZpbCnDLh","staticId":"ucms_7zPZpbCnDLh","title":"绿叶制药自愿公告","shareTitle":"绿叶制药自愿公告","thumbnail_doc":"","thumbnail":"","source":"","author":"","editorcode":"weMedia","editTime":"2020-09-01 15:12:05","updateTime":"2020\/09\/01 15:12:05","wapurl":"http:\/\/\/\/finance.ifeng.com\/c\/7zPZpbCnDLh","introduction":"","wwwurl":"http:\/\/\/\/finance.ifeng.com\/c\/7zPZpbCnDLh","commentsUrl":"ucms_7zPZpbCnDLh","commentCount":0,"text":"
每经AI快讯,绿叶制药(02186,HK)董事会宣布,集团用于治疗老年性痴呆的在研新药利斯的明透皮贴剂(多日贴)(LY03013)已获国家药品监督管理局药品审评中心(CDE)批准启动临床试验。<\/p>
(记者 袁东)<\/p>","img":[],"summary":"每经AI快讯,绿叶制药(02186,HK)董事会宣布,集团用于治疗老年性痴呆的在研新药利斯的明透皮贴剂(多日贴)(LY03013)已获国家药品监督管理局药品审评","sharesummary":"每经AI快讯,绿叶制药(02186,HK)董事会宣布,集团用于治疗老年性痴呆的在研新药利斯的明透皮贴剂(多日贴)(LY03013)已获国家药品监督管理局药品审评","commentType":"0","wemediaEAccountId":"373005","showclient":"0","shareurl":"https:\/\/ishare.ifeng.com\/c\/s\/v002lMPJ--mCeYmRV6qKDthjIuSThq0Salpxs2O5oO5UZZQ0__","praise":"0","like_num":"0"}}